Global Professional Acne Medication Market (2022 to 2030)

DUBLIN, January 19, 2022 /PRNewswire/ — The “Professional Acne Medication Market by Distribution Channel, By Acne Type, Therapeutic Class, By Formulation: Global Opportunity Analysis and Industry Forecast, 2022-2030” report has been added to from offer.

Research and Markets Logo

The professional acne medication market size was valued at $2.80 billion in 2021 and is expected to reach $5.45 billion by 2030 with a CAGR of 7.2% from 2022 to 2030.

Acne is one of the most common skin conditions caused by dead skin cells, oil excreted from the skin, and clogged hair follicles. It is characterized by whiteheads, blackheads, pimples and cysts. It affects millions of young people around the world. Also, the body parts most affected by acne are the face, shoulders, and upper chest and back. Acne treatment is done largely by drying out the skin, making it a less inviting place for the proliferation of acne-causing and acne-promoting microbes. It is done either by medication or therapeutically.

Market dynamics and trends

The demand for professional acne medications is increasing due to the increase in the prevalence of acne diseases. Furthermore, factors such as increasing teenage population, unhealthy urban lifestyle, and changes in hormone levels are expected to propel the market growth over the forecast period. Moreover, the desire to look beautiful and aesthetic, especially among young people, is driving the growth of the market. Also, increasing levels of pollution is another factor that leads to skin problems and in turn accelerates the demand for acne treatments in the market.

However, the presence of alternative treatments and side effects such as skin irritation, dry skin and skin redness due to the use of acne medications are the factors that are restraining the growth of the market during of the forecast period. On the other hand, high market potential in untapped emerging economies and development of effective drugs with fewer side effects are expected to provide lucrative growth opportunities for market growth.

Market Segmentation and Scope of the Study:

The professional acne market has been segmented based on distribution channel, acne type, therapeutic class, formulation, and geography. Based on the distribution channel, the market is divided into medical spa, beauticians, dermatologists and other professional channels. Based on the type of acne, the market is divided into non-inflammatory acne and inflammatory acne. Based on therapeutic class, the market is divided into retinoids, antibiotics, salicylic acid, benzoyl peroxide and others. The retinoid segment is further classified into topical retinoid and combination retinoid, and oral retinoid (isoretinion). The Antibiotics segment is further classified into topical antibiotics and combination antibiotics and oral antibiotics. Based on formulation, the market is divided into topical medications and oral medications. The geographic breakdown and analysis of each of the aforementioned segments includes regions comprising North America, Europe, Asia Pacific, and grip.

Geographical analysis

North America The region holds the lion’s share of the professional acne medication market and is expected to continue dominating the market over the forecast period. This is attributed to factors such as the increase in the use of skin care products and the increasing prevalence of this condition in this region. In addition, increased awareness of new drugs along with the presence of many other drugs in the pipeline of pharmaceutical companies, such as Johnson & Johnson, Pfizer Inc. and Bausch Health Companies Inc. are expected to drive demand for these products in the coming years. to come. year.

Asia Pacific, on the other hand, is expected to show a steady rise in the professional acne medication market owing to the high demand for acne treatments and rising healthcare expenditure along with increased awareness of new treatments developed that can replace conventional acne treatment in this area. Region. Moreover, the presence of major players such as The Derma Co., Skin Kraft, Soul Tree, and Plum Goodness is boosting the market growth in this region.

Competitive landscape

The market includes various players such as Almirall SA., Bausch Health Companies Inc., Johnson & Johnson, GlaxoSmithKline Plc (GSK), Galderma SA, Mayne Pharma Group Limited, Mylan NV, Sun Pharmaceutical Industries Limited, Pfizer Inc. and Teva Pharmaceutical Industries ltd. These manufacturers actively engage in R&D initiatives, product and technology innovations, and industry collaborations to improve their product and increase their growth and geographic reach.

Main topics covered:

1. Introduction

2. Professional Acne Drugs Market – Summary

3. Market Overview
3.1. Market definition and scope
3.2. Market dynamics

4. Covid-19 analysis
4.1. Impact on market size
4.2. End user trends and preferences, budget and economic impact
4.3. Key Players’ Strategies to Combat the Influence of Covid-19 in the Market

5. Market Share Analysis
5.1. Acne Medication Top Vendors Market Share Analysis 2020

6. Total number of medical spas by country

7. Global Professional Acne Medication Market, By Distribution Channels
7.1. Overview
7.2. medical spa
7.3. Beauticians
7.4. Dermatologist
7.5. Other Professional Channels

8. Global Professional Acne Medication Market, By Acne Type
8.1. Overview
8.2. Inflammatory acne
8.3. Non-inflammatory acne

9. Global Professional Acne Medication Market, By Therapeutic Class
9.1. Overview
9.2. Retinoids
9.3. Antibiotics
9.4. Salicylic acid
9.5. Benzoyl peroxide
9.6. Others

10. Global Professional Acne Medication Market, By Formulation
10.1. Overview
10.2. Topical medications
10.3. Oral medications

11. Global Professional Acne Medication Market, By Region
11.1. Overview
11.2. North America
11.3. Europe
11.4. Asia Pacific
11.5. Rest of the world

12. Company Profiles
12.1. Almirall S.A.
12.2. Bausch Health Companies Inc.
12.3. Johnson & Johnson
12.4. GlaxoSmithKline plc
12.5. Galderma
12.6. Mayne Pharma Group Limited
12.7. Viatris inc.
12.8. Sun Pharmaceutical Industries Limited
12.9. Pfizer Inc.
12.10. Teva Pharmaceutical Industries Ltd.

For more information on this report, visit

Media Contact:

Research and Markets
Laura Wood, senior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904
Fax (outside the US): +353-1-481-1716



Show original content:—opportunity-analysis-and-industry-forecast-301464022.html

SOURCE Research and Markets

About Thomas Hereford

Check Also

Pierre Fabre and Lonza enter into a manufacturing agreement for the W0180 antibody

Lonza will provide clinical drug manufacturing for W0180, an oncology drug candidate discovered by Pierre …